Sparsentan在中国上市了吗?好购买吗？

Introduction: Sparsentan is an oral dual endothelin angiotensin receptor antagonist developed by Travere Therapeutics for the treatment of immunoglobulin A (IgA) nephropathy and focal segmental glomerulosclerosis (FSGS). In February 2023, Sparsentan received accelerated approval in the United States for the reduction of proteinuria in adult patients with primary IgA nephropathy who are at risk for rapid disease progression.

Is Sparsentan available in China?

As of December 9, 2024, it has not been officially launched in China and cannot be purchased directly in China. Sparsentan, also called sparsentan, has dual antagonistic effects on endothelin I and angiotensin receptor II. By inhibiting the action of angiotensin II receptor, it reduces glomerular filtration protein. At the same time, it can also block the activity of endothelin receptor A and reduce the reabsorption of protein by renal tubules, thereby reducing proteinuria.

Is Sparsentan easy to buy?

Sparsentan is not currently on the market in China, so this drug cannot be purchased directly through formal domestic channels. The following are some possible purchase methods:

1. Purchase abroad: Patients can choose to go abroad to a country where Sparsentan is already on the market, and then purchase the drug at a local hospital pharmacy or drug store. If a patient is receiving medical treatment abroad and the doctor believes that Sparsentan is appropriate to treat his or her disease, the patient can purchase Sparsentan from the hospital pharmacy.

2. Overseas medical service institutions: If it is inconvenient for patients to go abroad, patients can purchase Sparsentan through domestic overseas medical service institutions. These institutions usually cooperate with multinational pharmaceutical companies to ensure the legality, safety and authenticity of the drugs. This method may be more economical and more convenient than purchasing abroad on your own.

3. Online pharmacies: In some countries and regions, Sparsentan may be sold in online pharmacies. Patients can consult these online pharmacies to understand the purchase process and related requirements.

Before purchasing and using Sparsentan, patients should consult a professional doctor for advice. At the same time, since Sparsentan is a prescription drug, patients must obtain a doctor's prescription before use.

Drug interactions of Sparsentan

1. Renin-angiotensin system (RAS) inhibitors and ERA: Do not coadminister Sparsentan with ARBs, ERAs, or aliskiren to avoid increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure).

2. Strong and moderate CYP3A inhibitors: Avoid using Sparsentan with strong CYP3A inhibitors at the same time. If the use of strong CYP3A inhibitors cannot be avoided, interrupt Sparsentan treatment. Consider dose titration when resuming Sparsentan therapy. Monitor blood pressure, serum potassium, edema, and renal function periodically during concurrent use with moderate CYP3A inhibitors. Concomitant use with strong CYP3A inhibitors increases Sparsentan exposure and may increase the risk of Sparsentan adverse reactions.

3. Strong CYP3A inducers: Avoid using Sparsentan with strong CYP3A inducers at the same time. Use with strong CYP3A inducers at the same time will reduce the exposure of Sparsentan, which may reduce its efficacy.